Table 2.
Changes in the Hematological and Biochemical Profiles After 2 Weeks of Treatment
| Parameter (units) | Group |
|||
|---|---|---|---|---|
| Normal | rhGH | FO 50 | FO 100 | |
| RBC (106/μL) | 6.67 ± 0.39 | 6.60 ± 0.19 | 6.79 ± 0.15 | 6.92 ± 0.30 |
| WBC (103/μL) | 3.18 ± 0.45 | 2.85 ± 0.42 | 2.66 ± 0.96 | 3.75 ± 0.96 |
| Hematocrit (%) | 48.81 ± 2.86 | 48.69 ± 1.26 | 49.46 ± 1.41 | 50.08 ± 2.29 |
| Hemoglobin (g/dL) | 14.24 ± 0.66 | 14.04 ± 0.28 | 14.31 ± 0.49 | 14.21 ± 0.59 |
| MCV (fL) | 73.16 ± 1.52 | 73.70 ± 1.93 | 72.90 ± 1.40 | 72.56 ± 1.40 |
| MCH (pg) | 21.34 ± 0.48 | 21.36 ± 0.59 | 21.06 ± 0.63 | 20.94 ± 0.34 |
| MCHC (g/dL) | 29.16 ± 0.40 | 28.88 ± 0.44 | 28.89 ± 0.57 | 28.99 ± 0.31 |
| Platelet (103/μL) | 1101.38 ± 257.49 | 1219.63 ± 130.72 | 1222.88 ± 218.25 | 1360.38 ± 181.24 |
| ALT (U/L) | 40.70 ± 7.09 | 39.50 ± 6.87 | 35.20 ± 6.89 | 37.90 ± 6.81 |
| AST (U/L) | 100.20 ± 11.42 | 92.40 ± 14.18 | 105.10 ± 11.42 | 101.70 ± 10.14 |
| BUN (mg/dL) | 14.36 ± 2.93 | 12.52 ± 1.38 | 13.51 ± 1.62 | 12.76 ± 1.26 |
| Creatinine (mg/dL) | 0.29 ± 0.05 | 0.28 ± 0.02 | 0.29 ± 0.03 | 0.29 ± 0.03 |
| Calcium (mg/dL) | 11.45 ± 0.59 | 11.44 ± 0.31 | 11.14 ± 0.25 | 11.22 ± 0.27 |
At day 14 after treatment, whole blood and serum were analyzed for hematological and biochemical evaluation. The data are expressed as the means ± standard deviation (SD, n = 19). The statistical analyses were conducted using analysis of ANOVA-Tukey's post hoc test between groups. All data showed that there is no statistically significant difference between groups. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen, MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, MCH concentration; RBC, red blood cells; WBC, white blood cells.